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OBJECTIVES: Anemia is a common complication among chronic kidney disease patients on hemodialysis,
occurring mostly due to erythropoietin deficiency. This randomized noninferiority trial sought to compare the
efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos, a biologics manufacturer
affiliated with the Brazilian government, with those of a commercially available product currently used in Brazil
(a biosimilar epoetin formulation).
METHODS: The sample size needed to enable demonstration of noninferiority with a statistical power of 85%
for a between-group difference in hemoglobin levels of no more than 1.5 g/dL was calculated. In total, 74
patients were randomly assigned to receive the epoetin formulation from Bio-Manguinhos (n= 36) or the
biosimilar epoetin formulation (n=38) in a double-blind fashion. The inclusion criteria were current epoetin
therapy and stable hemoglobin levels for at least 3 months prior to the study. The primary and secondary
outcomes were mean monthly hemoglobin levels and safety, respectively. The dose was calculated according to
international criteria and adjusted monthly in both groups according to hemoglobin levels and at the assistant
physicians’ discretion. Iron storage was estimated at baseline and once monthly. Clinicaltrials.gov:
NCT01184495.
RESULTS: The study was conducted for 6 months after randomization. The mean baseline hemoglobin levels
were 10.9¡1.2 and 10.96¡1.2 g/dL (p=0.89) in the Bio-Manguinhos epoetin and biosimilar epoetin groups,
respectively. During the study period, there was no significant change in hemoglobin levels in either group
(p=0.055, ANOVA). The epoetin from Bio-Manguinhos was slightly superior in the last 3 months of follow-up.
The adverse event profiles of the two formulations were also similar.
CONCLUSIONS: The epoetin formulations tested in this study are equivalent in efficacy and safety.
KEYWORDS: Epoetin Alfa; Randomized Controlled Trial; Chronic Kidney Disease; Anemia; Hemodialysis;
Erythropoietin.
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& INTRODUCTION
Anemia is a common complication among chronic kidney
disease (CKD) patients on hemodialysis, occurring mostly
due to erythropoietin deficiency (1). In these patients,
replacement therapy with recombinant human erythropoie-
tin (epoetin alfa) leads to decreased transfusion require-
ments, fewer hospital admissions and improved physical
and cognitive performance status, with consequent
improvements in quality of life (2-5). In Brazil, epoetin alfa
is provided free of charge through the Unified Health
System for patients who meet clinical practice guideline
criteria (6) and is used by approximately 80-90% (7-9) of
the more than 90,000 patients undergoing hemodialysis
in the country; 85% of these doses are funded by the
government (8).
Since September 2006, Laborato´rio Bio-Manguinhos (run
by the Oswaldo Cruz Foundation, a constituent organization
Copyright  2014 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
DOI: 10.6061/clinics/2014(08)08
CLINICAL SCIENCE
547
of the Brazilian Ministry of Health) has manufactured and
distributed the epoetin alfa dispensed to CKD patients across
all Brazilian states. It is of the utmost importance that this
product be widely accepted by health care providers and the
patient community alike.
The objective of this study was to conduct a head-to-head
noninferiority trial comparing the epoetin alfa formulation
manufactured by Bio-Manguinhos with a biosimilar for-
mulation previously used by state and municipal depart-
ments of health throughout the country.
& MATERIALS AND METHODS
To compare the efficacy of the two products containing
recombinant human epoetin alfa, a randomized double-
blind noninferiority trial design was used. The criteria for
inclusion were age .18 years, hemodialysis with subcuta-
neous epoetin alfa treatment of at least 3 months’ duration,
baseline ferritin .100 ng/mL, baseline transferrin satura-
tion .20%, Kt/V .1.2 and provision of written informed
consent to participate in the study. Patients with hemolytic
anemia, myelodysplastic syndrome, multiple myeloma,
thalassemia, pancytopenia, sickle cell disease, neoplasms,
chronic inflammatory conditions or active bleeding were
excluded.
A convenience sampling strategy was used. All CKD
patients undergoing hemodialysis at the two participating
study centers were considered as potential candidates, as
long as they met the aforementioned inclusion criteria.
The patients were recruited and screened at two dialysis
centers in Porto Alegre, state of Rio Grande do Sul, Brazil,
in May and June 2008. Randomization was stratified by the
presence of diabetes and the usual epoetin alfa dose,
defined as high (weekly dose .150 IU/kg) or low (weekly
dose ,150 IU/kg). The patients were randomly allocated
to receive epoetin alfa manufactured by Bio-Manguinhos
(Fiocruz) or a biosimilar formulation (Alfaepoetina
BlausiegelH) by a statistician, who did not participate in
the project, using a computer-generated randomization
sequence (randomization.com).
The follow-up period was 6 months long. In both groups,
all subjects were seen monthly by the study physicians; their
test results were reviewed, and their epoetin dose was
adjusted as necessary to keep hemoglobin levels in the 11-
12 g/dL range. The physicians and all other personnel
remained blind to the treatment allocation. Furthermore,
also in a blind fashion, all patients received maintenance
doses of parenteral iron as necessary to keep serum ferritin
.100 ng/mL. Dose adjustment was performed monthly for
all subjects. Adverse events were assessed by a chart review,
as well as during monthly patient interviews that were
conducted by study nurses.
The blinding was performed by two pharmacists, one at
each study center, who had sole access to the randomization
tables and were exclusively responsible for the receipt,
storage and dispensing of the medications. Neither phar-
macist played any role in patient care or had any contact
with the study center staff involved in patient care. During
the shift immediately preceding scheduled epoetin admin-
istration, the study pharmacists labeled and preloaded
syringes with the appropriate epoetin dose for each patient,
which were then stored in an appropriate container
under refrigeration. The study nurses administered the
drugs without any knowledge of the dose or product.
The sample size needed for a statistical power of 85% and
a significance level of 5% was calculated. The ideal sample
size was estimated at 70 subjects (35 in each treatment
group), taking into account a rate of loss to follow-up of up
to 15%. The sample size calculations assumed that both
treatments would prove equivalent (with a mean difference
in hemoglobin levels no greater than 1.5 g/dL).
The primary outcome of interest was the hemoglobin
level and its variation over a 6-month follow-up period in
both treatment groups. The secondary outcomes were the
epoetin dose and safety variables (as assessed by the
adverse event rate).
Statistical analysis
The data were stored in a Microsoft Access database and
analyzed in the SPSS 14.0 software environment.
Analysis of variance (ANOVA) was used to compare
hemoglobin values and their fluctuation over time between
the two treatment groups. The proportion of patients
achieving the target hemoglobin range in each group was
measured and the chi-square test was used for between-
group comparison. Epoetin alfa doses (mean¡SD), read-
justed monthly in each group throughout the study period,
were also compared by ANOVA.
Statistical analyses were conducted on an intention-to-
treat basis using repeated-measures ANOVA (with the
last observation carried forward). The same method was
used for the between-group comparison of other variables,
including hematocrit, serum iron, serum potassium and the
urea reduction rate (URR).
Figure 1 - Flow chart of patient enrollment and follow-up.
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& ETHICS
The study was approved by the Hospital de Clı´nicas
de Porto Alegre Research Ethics Committee (Institutional
Review Board-equivalent) and registered at clinicaltrials.gov
(Efficacy Study of Two Formulations of Erythropoietin/
NCT01184495, http://clinicaltrials.gov/ct2/show/NCT01184495?
term=NCT01184495&rank=1). The study was conducted in
accordance with the provisions of the Declaration of Helsinki.
All subjects provided written informed consent.
& RESULTS
A total of 86 patients were screened and 74 were found to
be eligible for randomization. Center A randomized 21
patients: 10 to Bio-Manguinhos epoetin (EpoBM) and 11 to
the biosimilar formulation (EpoBS). Center B randomized 53
patients: 26 to EpoBM and 27 to EpoBS. Overall, 36 patients
were allocated to receive EpoBM and 38 were allocated to
receive EpoBS.
Loss to follow-up
In total, 22 patients dropped out of the study over a 6-
month period: one due to screening failure, seven due to
death, three due to transfusion requirements, three due to
surgical intervention, two who were switched to other
treatment modalities, three who were lost to follow-up,
two who received renal allografts and one who withdrew
informed consent (Figure 1).
Sample profile
The two experimental groups showed no statistically
significant differences in the study parameters at baseline
(Table 1). There were no significant between-group differ-
ences in serum hemoglobin, ferritin, iron or parathyroid
hormone (PTH) levels; in the URR; or in the proportion of
patients with diabetes. Anthropometric parameters were
similar. Female patients were slightly predominant in the
EpoBS group, with no statistical significance. The percen-
tage of patients receiving epoetin at doses higher than
150 IU/kg/month was also similar between the EpoBM and
EpoBS groups (31.6% vs. 27.8%, respectively; p= 0.721).
Hemoglobin values, biochemical parameters and
epoetin dose
There were no significant between-group differences in
hemoglobin levels, whether at baseline or during the 6-
month follow-up. Throughout the observation period, mean
hemoglobin levels remained within the target range of 10-
12 g/dL in both groups. Over the final 3 months of the
study, mean monthly hemoglobin levels were slightly
higher in the EpoBM group, but this difference did not
reach statistical significance (p= 0.112). Hemoglobin levels
were similar between diabetic and nondiabetic patients,
regardless of the epoetin formulation used (p= 0.112).
Epoetin alfa doses (in IU/kg/month), adjusted as neces-
sary from the first month of follow-up to keep hemoglobin
levels in the target range of 11-12 g/dL, were also similar
between the two groups (Table 2 and Figure 2). Two-way
repeated-measures ANOVA for this variable (epoetin dose)
showed that there were no significant differences from
month to month throughout the study period. Regarding
the mean monthly dose of epoetin alfa used in this study,
there was a 25% increase in the EpoBM dose from baseline to
month 5 and a 17% increase in the EpoBS dose in the same
period. However, this difference did not reach statistical
significance. The patients’ iron reserves (as measured based
on ferritin and iron levels and iron-binding capacity)
remained adequate throughout the study period, with no
between-group differences (p= 0.314, 0.279 and 0.2, respec-
tively, ANOVA). Serum potassium levels also remained
similar between the two treatment groups throughout the
study (p= 0.559, ANOVA). Finally, the URR remained within
the recommended range (URR.65%) in all patients, with no
significant between-group differences (p= 0.31, ANOVA).
Table 1 - Sample profile (by study group).
Characteristic Bio-Manguinhos EPO Biosimilar EPO p-value
N 36 38 —
Male 50% (19) 38.9% (14) 0.34
Diabetes mellitus 36.8% (14) 38.9% (14) 0.86
Dose .150 IU/kg/week 31.6% (12) 27.8% (10) 0.72
Height (cm) 164.7¡10.2 162.3¡12.1 0.37
Weight (kg) 66.7¡16.5 63.6¡13.7 0.39
Age (years) 54.6¡15.6 59.5¡13.5 0.16
Baseline
hemoglobin (g/dL)
10.9¡1.2 10.96¡1.2 0.89
Baseline
hematocrit (%)
34.24¡3.8 34.6¡3.6 0.67
Baseline
ferritin (ng/mL)
663.5¡384.3 623.4¡301.2 0.62
Iron (mg/dL) 80.4¡37.5 68.1¡25.0 0.10
URR 70.6¡7.2 72.2¡10.8 0.46
PTH (pg/mL) 434.0¡393.6 503.7¡411.1 0.49
PTH: parathyroid hormone. URR: urea reduction rate.
Table 2 - Epoetin alfa dose used and hemoglobin values (mean¡SD) by patient group.
Mean monthly total dose of
prescribed EpoBM
Bio-Manguinhos Hbb
g/dL¡SD
Mean monthly
total dose of prescribed EpoBS
Biosimilar Hgb
g/dL¡SD
Baseline 31.6 used doses .150 UI/kg/week 10.92¡1.23 27.8 used doses .150 UI/kg/week 10.96¡1.20
Month 1 32342.9 10.76¡1.65 30305.8 11.07¡1.81
Month 2 36114.2 10.63¡1.46 27243.7 11.03¡1.95
Month 3 41371.4 11.11¡1.43 31157.9 10.91¡1.97
Month 4 40685.7 11.52¡1.60 34315.8 11.05¡1.93
Month 5 40000.0 11.59¡1.53 35473.7 10.98¡1.70
Month 6 38514.3 11.45¡1.74 36931.5 11.07¡1.66
ANOVA for the change in the mean EPO dose used was not significant; p=0.361.
ANOVA for mean hemoglobin levels; p=0.055.
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Figure 2 - Mean hemoglobin levels during the 6-month follow-up in (A) the groups receiving Bio-Manguinhos epoetin (EpoBM) or a
commercially available biosimilar formulation (EpoBS) and in (B) diabetic and nondiabetic patients. (C) Mean monthly doses of epoetin
alfa in the EpoBM and EpoBS groups.
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Adverse events
Table 3 shows the frequency of undesirable signs and
symptoms experienced by patients during the study and
reported during the monthly interviews. Although adverse
effects were relatively common, their incidence was similar
between the two treatment groups (p= 0.70). Similarly, we
found no significant difference in the incidence of severe
adverse events (Table 4). Seven patients developed vascular
access thrombosis (12 episodes in total). Two patients in the
EpoBM group died, compared with five in the EpoBS group;
this difference did not reach statistical significance (RR
0.434, 95% CI 0.090-2.096). The cause of death was infection
or cardiovascular disease in three cases each and hypogly-
cemia in the remaining case. No deaths were related to the
type of epoetin used.
& DISCUSSION
This was the first randomized double-blind clinical trial
designed to compare the efficacy of epoetin alfa manufac-
tured by Bio-Manguinhos with that of a biosimilar formula-
tion. The chosen comparator product was Alfaepoetina
BlausiegelH, which was regularly distributed by the Rio
Grande do Sul state health system until December 2006.
Our results show no between-group difference in hemo-
globin levels or epoetin alfa doses throughout the 6-month
follow-up period. Mean hemoglobin levels remained within
the predefined target range throughout the study.
The target hemoglobin range was defined according to
recommendations in the current literature (10,11). A more
recent study suggested that higher hemoglobin targets are
associated with cerebrovascular events and no improve-
ment in quality of life in this patient population (12).
At the end of the study period, one-third of the patients in
each group had hemoglobin levels in the 11-12 g/dL range,
with no between-group differences. Certain authors (13-15)
recommend that hemoglobin values be kept in the range of
10-12 g/dL. In the current study, using this recommenda-
tion, 60% of patients in both groups were within the target
range every month. These findings are similar to those
reported elsewhere in the literature (16-18). In a multicenter
study of 24,948 patients receiving hemodialysis at 135 U.S.
centers, only 38.4% of patients had hemoglobin levels in the
11-12 g/dL range (19). Another observational study of 987
patients (17) found that mean hemoglobin levels fluctuated
between 10.9 and 11.2 g/dL over a 6-month period, with
less than 50% of patients remaining within the recom-
mended therapeutic range.
As is the norm for biological variables, hemoglobin ranges
exhibit a degree of variation with repeated measurement
(20-22). In patients with CKD, this variability is even greater
(23) due to a combination of factors, which include patient
characteristics, intercurrent events, and clinical practice and
care patterns (19,24,25).
In the present study, the epoetin alfa dose was readjusted
once monthly, in compliance with Brazilian Health
Surveillance Agency Resolution 145, which established that
hemodialysis patients should undergo monthly hematocrit
and hemoglobin measurements to be consistent with
current medical practice. Variability in hemoglobin levels
and in the number of patients outside recommended
hemoglobin ranges might decrease if doses are adjusted
more often (26). From baseline to months 4 and 5, the mean
monthly dose of epoetin alfa was higher in the EpoBM
group. However, the investigators blindly decided the dose,
which might have been the cause of the slightly higher
hemoglobin levels noticed in this group at the end of the
trial. A longer observation period would be required to
enable us to better compare these ‘ups and downs’ between
groups.
The leading causes of death in the study were cardiovas-
cular disease and infection, as usually occur in patients with
dialysis-dependent chronic renal failure (27,28).
The frequency of signs and symptoms reported by
patients during treatment and considered to be adverse
effects was similar between the two groups, reflecting the
high morbidity of CKD (27,28). These manifestations are
part of the uremic syndrome and cannot be fully corrected
by current dialysis therapies; renal transplantation is
required. Seven hemodialysis-related thrombotic events
(associated with vascular access) occurred during the course
of the study. Thrombotic events are relatively common
in patients undergoing dialysis, occurring at a rate of
approximately 0.5-0.8 patients/year (29). The overall A-V
fistula thrombosis rate found was 12/74 (16.3%) (30),
with no between-group difference (31). This multifactorial
adverse event might have been related to the dose of epoetin
in both arms, but this relationship still has not been clearly
established in the literature (32). Vascular access thrombosis
is related to a variety of factors, including the type of access,
care and management of the access (33) and higher anemia
correction targets (34,35). Furthermore, this thrombosis is
even more common in patients with preexisting cardiovas-
cular disease (34). However, due to the small sample size of
the present study, we were unable to draw any definitive
conclusions regarding this complication.
In conclusion, the recombinant human erythropoietin
(epoetin alfa) manufactured by the Immunobiologics
Table 3 - Number of adverse events reported by patients
during monthly follow-up interviews.
Adverse event Bio-Manguinhos Biosimilar Overall
Fatigue 52 51 103
Arthralgia 64 60 123
Headache 37 49 86
Nausea/vomiting 37 38 75
Fever 4 5 9
Chest pain 27 28 55
Edema 22 20 42
Palpitations 22 23 45
Diarrhea 21 19 40
Dyspnea 18 13 31
Pruritus/hives 43 36 79
None 64 78 142
Total 411 420 830
Table 4 - Severe adverse events.
No. severe
AEs/patient
Bio-Manguinhos
N (%)
Biosimilar
N (%)
Overall
N (%)
None 18 (50.0) 22 (57.9) 40 (54.1)
1 13 (36.1) 10 (26.3) 23 (31.1)
2 1 (2.8) 3 (7.9) 4 (5.4)
3 3 (8.3) 2 (5.3) 5 (6.8)
5 1 (2.8) 0 1 (1.4)
7 0 1 (2.6) 1 (1.4)
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Technology Institute of the Oswaldo Cruz Foundation (Bio-
Manguinhos, Fiocruz, Brazilian Ministry of Health) exhib-
ited efficacy and safety results comparable to those of a
commercially available biosimilar formulation in a sample
of CKD patients undergoing hemodialysis. There were no
between-group differences in the adverse event rate at any
point during the study period. The Brazilian Ministry of
Health estimates that domestic manufacturing of epoetin
has saved the public approximately US$ 20 million per
year. Brazilian manufacturing of a recombinant polypeptide
represents massive progress for a country whose biophar-
maceutical development technology is at least 30 years
behind the state of the art. Incorporation of this technology
by a national public laboratory creates the possibility
of manufacturing a wide range of other biotechnological
products, a possibility that has already been realized at
Bio-Manguinhos/Fio-Cruz. Government manufacturing of
high-technology pharmaceutical products is vital to coun-
tries that distribute and dispense such products through
universal health systems, such as Brazil, which has made
epoetin freely available nationwide.
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